1,4-二氢-4-氧代-3-喹啉羧酸乙酯 | 52980-28-6

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1,4-二氢-4-氧代-3-喹啉羧酸乙酯
• 中文别名: 4-氧代-1,4-二氢喹啉-3-甲酸乙酯；4-羟基-3-乙氧羰基喹啉；4-羟基-3-喹啉羧酸乙酯；4-氧代-1,4-二氢-3-喹啉甲酸乙酯；3-乙氧羰基-4-羟基喹啉；4-氧代-1,4-二氢喹啉-3-羧酸乙酯；4-氧代-1H-3-喹啉羧酸乙酯；4-氧代-1H-喹啉-3-甲酸乙酯
• 英文名称: 4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester
• 英文别名: ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate；ethyl 4-oxo-1H-quinoline-3-carboxylate
• CAS: 52980-28-6
• 化学式: C₁₂H₁₁NO₃
• mdl: MFCD00173406
• 分子量: 217.224
• InChiKey: YBEOYBKKSWUSBR-UHFFFAOYSA-N

物化性质

• 熔点：
  270°
• 沸点：
  343.7±42.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMF（轻微加热）、DMSO（轻微加热）

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 4-oxo-1,4-dihydro-3-quinolinecarboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 4-oxo-1,4-dihydro-3-quinolinecarboxylate
CAS number: 52980-28-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H11NO3
Molecular weight: 217.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,4-二氢-4-氧代-3-喹啉羧酸乙酯 在 氯化亚砜 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 2-苯基-1H-吡唑并[4,5-c]喹啉-3-酮
  参考文献：
  名称：

  作为潜在的检查点激酶1（Chk1）抑制剂的2-芳基-2H-吡唑并[4,3-c]喹啉-3-酮的合成及其初步的构效关系研究。

  摘要：

  丝氨酸-苏氨酸检查点激酶1（Chk1）在细胞周期停滞中起着至关重要的作用，以响应DNA损伤。在过去的十年中，Chk1抑制剂已成为增强细胞毒性化学治疗剂抗肿瘤功效的新型治疗策略。在寻找新的Chk1抑制剂时，首次通过体外和计算机模拟方法评估了同类的2-芳基-2 H-吡唑并[4,3-c]喹啉-3-酮（PQ）。 。使用常规或微波加热以良好至极好的产率合成了总共30个PQ结构，突出显示其中14个是新的化学实体。值得注意的是，在这项初步研究中，两种化合物4e2和4h2已显示Chk1激酶的基础活性适度但显着降低。从这些初步结果开始，

  DOI：

  10.1080/14756366.2017.1404592
• 作为产物：
  描述：

  2-硝基苯甲酰乙酸乙酯 在 氢气 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 12.0h， 生成 1,4-二氢-4-氧代-3-喹啉羧酸乙酯
  参考文献：
  名称：

  依伐卡托的高效合成

  摘要：

  依伐卡托的新型实用合成路线以克为单位描述。通过在芳族环上亲电加成两个叔丁基，可制备纯度为98.1％的3个步骤，收率61％的5-氨基-2,4-二叔丁基苯酚（高效液相色谱法）。3-二（2-氨基苯基）-3-氧代丙酸乙酯的分子内环化与二甲基甲酰胺的动力学力学分析用于在四个步骤中以54％的收率制备4-氧代-1,4-二氢喹啉-3-羧酸。依伐卡托是通过两个部分的缩合获得的，产率为71％，纯度为99.1％（高效液相色谱法）。

  DOI：

  10.1002/jhet.2931
• 作为试剂：
  描述：

  5-(Benzyloxy)-2,4-di-tert-butylaniline 、 1,4-二氢-4-氧代-3-喹啉羧酸乙酯 在 1,4-二氢-4-氧代-3-喹啉羧酸乙酯 作用下， 以71.3的产率得到N-(5-(Benzyloxy)-2,4-di-tert-butylphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
  参考文献：
  名称：

  化合物的制备方法

  摘要：

  本发明提供了制备式I所示化合物的方法，该方法包括：(1)将式1所示化合物进行硝化反应，以便获得式2所示化合物；(2)利用苄基氯对式2所示化合物进行羟基保护处理，以便获得式3所示化合物；(3)将式3所示化合物进行还原反应，以便获得式4所示化合物；(4)将式5所示化合物与苯胺接触，以便获得式6所示化合物；(5)将式4所示化合物与式6所示化合物接触，以便获得式7所示化合物；(6)将式7所示化合物进行羟基脱保护反应，以便获得式I所示化合物。本发明的合成方法路线短、操作简单、原料易得、收率高、最终产物纯度高、适合工业化生产。

  公开号：

  CN103787968A

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] HETEROCYCLIC DERIVATIVES FOR TREATMENT OF HYPERLIPIDEMIA AND RELATED DISEASES<br/>[FR] DERIVES HETEROCYCLIQUES POUR LE TRAITEMENT DE L'HYPERLIPIDEMIE ET DE MALADIES ASSOCIEES
  申请人：AVANIR PHARMACEUTICALS

  公开号：WO2005123686A1

  公开（公告）日：2005-12-29

  The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases.

  本发明提供了适用于增强哺乳动物体内逆向胆固醇转运的组合物。这些组合物适合口服给药，并可用于治疗和/或预防高胆固醇血症、动脉粥样硬化及相关心血管疾病。
• 一种哌尼诺安类似物及其制备方法和用途
  申请人：中国海洋大学

  公开号：CN108690024A

  公开（公告）日：2018-10-23

  本发明涉及一类哌尼诺安类似物,或其互变异构体、立体异构体、外消旋体、对映异构体的非等量混合物、几何异构体、溶剂化物、药学上可接受的盐或前药,以及包含该化合物的药物组合物。本发明还公开了这类化合物及其药物组合物作为药物,尤其是作为抗病毒、抗菌及抗寄生虫药物的用途。
• [EN] AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE<br/>[FR] AGENTS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES ET INFLAMMATOIRES AYANT UNE STRUCTURE BASÉE SUR LA 4(1H)-QUINOLONE
  申请人：UCL BUSINESS PLC

  公开号：WO2015189560A1

  公开（公告）日：2015-12-17

  The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of a cardiovascular disease or of an inflammatory disease or condition:

  本发明提供了一种式I的化合物，其互变异构体，或其药用可接受的盐或N-氧化物，用于治疗或预防心血管疾病或炎症性疾病或症状。

表征谱图